DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on July 13, 2026 has been entered.
Applicant’s amendments have overcome the objections to the specification and the rejections under 35 USC 112(b).
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 3-7, 9-14, and 16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
Claim 1 is drawn to an African Swine Fever Virus (ASFV) subunit vaccine comprising a glycosylated CD2V expressed in a eukaryotic system, a trimeric p72, and pharmaceutically acceptable water-in-oil-in-water (W/O/W) emulsion adjuvant. There is no guidance provided for these claimed components functioning as an effective vaccine. Tables 2 and 3 and paragraph [0041] of the instant published disclosure, USPgPub 2023/0265129 (of record), discuss efficacy of “vaccine 3” and “vaccine 4” formulations comprising CD2v and p72 trimer content of 40% and 71.79%, respectively. While the efficacy data of “vaccine 3” and “vaccine 4” formulations is encouraging, it is not clear what is administered or whether protective efficacy would be predicted by the skilled artisan (discussed below).
Regarding the trimeric forms of p72 recited in the claims, Cui et al. (ACS Infectious Diseases. 2025 Jul 9;11(8):2104-15, of record) discuss difficulty in forming trimeric forms of p72 due to susceptibility to misfolding and dependence on specific post-translational modifications. At the bottom of the page under “Main”, Cui et al. state “previous attempts to utilize recombinant P72 in subunit vaccine development have been hindered by its tendency to form monomers rather than the more immunogenic native trimers and the requirement for chaperone pB602L for folding.” Cui et al. also discusses poor immunogenicity due to improper folding in the Discussion section. In the paragraph above “Methods and Materials”, Cui et al. admits it is not known whether neutralizing antibodies are induced against membrane-bound, secreted, and intracellular forms of P72 and immunogenicity was not assessed.
The instant specification fails to describe how to make the requisite subunit components. Paragraph [0026] of the instant published disclosure, USPgPub 2023/0265129, states:
[0026] 1.1 Refer to the preparation method of African swine fever exterior envelope subunit protein CD2V of Application No. 201910004596.5 or 201910069838.9 of the applicant, or the preparation method of the exterior envelope subunit protein CD2V derived from African swine fever virus of other patents or documents (prokaryotic expression system expression, such as CHO, 293T cells, etc.).
Paragraph [0027] of the instant published disclosure states:
[0027] 1.2 Reference document is Structure of the African swine fever virus major capsid protein written by Liu Q, Ma B, Qian N, et al., p72. Cell Res. 2019; 29 (11): 953-955. Or other protein expression modes (such as the eukaryotic expression system, the insect baculovirus expression system, the CHO cell expression system, etc). Or the preparation method of African swine fever virus subunit protein p72 of other patents or documents. The content of the trimer reaches more than 40%.
In the first paragraph, Liu et al. (Cell Res. 2019; 29 (11): 953-955, of record) teach the “major capsid protein (MCP) p72 is the most dominant structural component of the virion and constitutes about ~31%–33% of the total mass of the virion.” It is not evident how the content of the instant trimer reaches more than 40%, as recited in instant claims 1 and 12.
Paragraph [0027] further describes peaks depicted in Figure 1. Peak 4 is attributed to the p72 protein trimer because its molecular weight is between 158 kDa and 440 kDa. However, there is no data provided for p72 trimer configuration. Cui et al. supra teach SDS-PAGE analysis under non-reducing conditions revealed a band approximately 240 kDa (Fig. 1G), trimer formation. The range in molecular weight between 158 kDa and 440 kDa, attributed to Peak 4 in paragraph [0027] does not possess specificity for identifying the trimeric form of p72.
The skilled artisan would not predict a formulation comprising glycosylated CD2v expressed in a eukaryotic system, a trimeric p72, and pharmaceutically acceptable adjuvant would be effective as an ASFV vaccine, as asserted by claims 1, 3-7, 9-14, and 16.
Because the instant CD2v protein is glycosylated and expressed in a eukaryotic system, viral vectored-derived proteins combined in a cocktail formulation appear to be within the scope of the instant claims. Lopera-Madrid et al. (Veterinary Immunology and Immunopathology. 2017; 185: 20-33) teach priming with (eukaryotic) human embryonic kidney 293 (HEK)-purified antigens: p72, p54, and p12 and boosting with three MVA-vectored antigens: p72, EP153R, and CD2v in the abstract, section 2.6. Therefore, the formulation of Lopera-Madrid et al. exposes pigs to more p72 than any other antigen in the formulation, similar to the “content of the trimeric protein is not less than 40% of the total content of the exterior envelope subunit protein p72 derived from African swine fever virus”, instantly claimed. However pigs that were administered MVA-ASFV construct cocktails failed to generate detectable ASFV antibody responses, but T-cell proliferative and IFN-γ T-cell responses were detected following HEK-ASFV antigen boost. While the cytotoxic immune response taught by Lopera-Madrid et al. is encouraging, immune determinants for ASFV protection have not been elucidated, see section 4 of Gaudreault et al. (Vaccines. 2019 Jun 25; 7 (2): 56, of record).
In section 3.1, Gaudreault et al. teach CD2v is not a strong immunogenic antigen, and high doses of the protein would likely be required to induce good protection. It is unclear whether the quantity ranges recited in instant claims 4-6, 12, and 13 would be sufficient. In Table 1, Gaudreault et al. teach baculovirus-expressed proteins, including p72, combined with Freund’s adjuvant resulted in a slight delay of clinical disease and viremia, but no protection.
Neilan et al. (Virology. 2004; 319: 337– 342, of record) teach neutralizing antibodies to ASFV p72 does not provide protection.
Cadenas-Fernández et al. (Pathogens. 2020 Feb 28; 9 (3): 171, of record) teach an adenovirus-vectored ASFV cocktail of thirty-five ASFV antigens, including p72 and a modified CD2v (EP402R∆PRR), failed to elicit protective efficacy, required of a vaccine, see the abstract, sections 2.2, 3.2, and 3.3.
Lokhandwala et al. (Veterinary Microbiology. 2019; 235: 10-20, of record) teach a nine-ASFV-antigen cocktail including p72 and a modified CD2v antigen, EP402RΔPRR administered prior to challenge, see section 2.4.2. When Lokhandwala et al. formulated the cocktail in BioMize adjuvant, strong IgG responses were induced, but when challenged, the vaccinees had more severe reaction relative to the controls. In the abstract, Lokhandwala et al. teach a “seven antigen cocktail-(II) was evaluated using two adjuvants: BioMize and ZTS-01. The BioMize formulation induced stronger antibody responses, but 8/10 vaccinees and 4/5 controls succumbed to the disease or reached experimental endpoint at 17 days post-challenge. In contrast, the ZTS-01 formulation induced weaker antibody responses, but 4/9 pigs succumbed to the disease while the 5 survivors exhibited low clinical scores and no viremia at 17 days post-challenge, whereas 4/5 controls succumbed to the disease or reached experimental endpoint. Overall, none
of the immunogens conferred statistically significant protection.” See sections 3.2 and 3.3.
Regarding the newly recited W/O/W emulsion adjuvant, the instant disclosure lists MONTANIDE™ ISA 206 VG and MONTANIDE™ ISA 201 VG as exemplative W/O/W emulsions. Wu et al. (Pathogens. 2024 Aug 21; 13 (8): 706, of record) list Montanide™ ISA as adjuvant types in ASFV vaccines, see section 3.2. In section 3.2.1, Wu et al. review the teachings of Zajac et al., administering a mixture of ASFV antigens expressed from adenoviruses, combined with Montanide ISA-201™. Zajac et al. achieved a humoral immune response, but no protective efficacy after challenge. Wu et al. also review the administration of irradiation-inactivated ASFV (comprising p72 and CD2v) combined with Montanide ISA-201™, resulting increased antibody titers against p72, but no protection against challenge. In sections 2.3.1, 2.3.2, 2.4.1, 2.4.2, and Table 1, Wu et al. describe the identification of T- and B-cell epitopes from p72 and CD2v, with some encouraging data. However, the T- and B-cell epitopes from p72 and CD2v discussed by Wu et al. are outside the scope of the instant p72 and CD2v subunit proteins because it is not evident that the epitopes reviewed by Wu et al. are sufficiently presented in the instant subunit vaccine. In the first full paragraph on page 11, Wu et al. teach ASFV subunit vaccines have a high safety profile, but have not demonstrated protective efficacy. Wu et al. conclude (in the same paragraph):
This indicates that there are many unknowns that need to be addressed with protective antigens or epitopes, adjuvants, and non-structural viral protein antigens in the development of new ASFV vaccines.
Therefore, the skilled artisan would not conclude that the combination of p72, CD2v, and a W/O/W adjuvant, encompassed by the instant claims, would be efficacious.
The state of the art indicates that African swine fever (ASF) is a viral disease of domestic and wild swine for which there is currently no vaccine or treatment available. For these reasons, it is determined that an undue quantity of experimentation would be required of the skilled artisan to make and use the invention claimed.
Response to Arguments
In reply to the rejection of record, applicant asserts that the instant specification provides significant guidance to make the claimed CD2v and p72 trimer protein components in paragraphs [0026-0027], respectively.
Applicant’s arguments and a review of instant paragraphs [0026-0027] have been fully considered, but are found unpersuasive. The instant specification fails to describe how to make the requisite subunit components. Paragraph [0026] of the instant published disclosure, USPgPub 2023/0265129, states:
[0026] 1.1 Refer to the preparation method of African swine fever exterior envelope subunit protein CD2V of Application No. 201910004596.5 or 201910069838.9 of the applicant, or the preparation method of the exterior envelope subunit protein CD2V derived from African swine fever virus of other patents or documents (prokaryotic expression system expression, such as CHO, 293T cells, etc.).
It is evident from this paragraph that the information provided in Application Nos. 201910004596.5 or 201910069838.9 are essential for the requisite glycosylation expressed in a eukaryotic system. Essential information from these sources is not included in the instant published disclosure.
The skilled artisan would not predict the eukaryotic glycosylation patterns or materials present on the instant CD2v. Pérez-Núñez et al. (Journal of Virology. 2023 Sep 28; 97 (10): e01030-23) demonstrate N-glycosylation at the N-terminus of CD2v and the integrity of the CD2v-signal peptide are essential for hemadsorption (HAD) virulence of African swine fever virus, while aspartic acid to glutamic acid mutations on specific N-terminal N-glycosylation sites prevent HAD. See the abstract, “HAD directly depends on CD2v-Nt domain during ASFV infection”, “CD2v-Nt N-glycosylation is essential for HAD”, “Signal peptide deletion prevents glycosylation and HAD of both CD2v-FL and CD2v-Nt” Figures 2, 3, 6, and 7. There is no teaching or data presented in the instant disclosure indicating whether the instant eukaryote-glycosylated CD2v possesses virulent HAD glycosylation sites and/or the HAD signal peptide and/or glycosylated aberrations abolishing HAD. Therefore, the skilled artisan would not have the requisite information required to make an efficacious eukaryotic-glycosylated-CD2v, as claimed.
Paragraph [0027] of the instant published disclosure states:
[0027] 1.2 Reference document is Structure of the African swine fever virus major capsid protein written by Liu Q, Ma B, Qian N, et al., p72. Cell Res. 2019; 29 (11): 953-955. Or other protein expression modes (such as the eukaryotic expression system, the insect baculovirus expression system, the CHO cell expression system, etc). Or the preparation method of African swine fever virus subunit protein p72 of other patents or documents. The content of the trimer reaches more than 40%.
It is not evident how the content of the trimer reaches more than 40%, as recited in instant claims 1 and 12. In the first paragraph, Liu et al. (Cell Res. 2019; 29 (11): 953-955, of record) teach the "major capsid protein (MCP) p72 is the most dominant structural component of the virion and constitutes about ~31%-33% of the total mass of the virion." There is no teaching in the instant disclosure or the prior art for achieving a "content of the trimeric protein is not less than 40% of the total content of the exterior envelope subunit protein p72 derived from African swine fever virus", as claimed.
Instant paragraph [0027] further describes peaks depicted in Figure 1:
…As shown in FIG. 1,…the peak volume of Peak 4 is 15.84 ml, and its molecular weight is between 158 kDa and 440 kDa, which is a p72 protein trimer (the molecular weight of p102M32 protein trimer is about 232 kDa);…
However, there is no data provided for p72 trimer configuration. Cui et al. supra characterize P72 trimers by SDS-PAGE analysis under non-reducing conditions that depicts a band approximately 240 kDa, see “P72 (T)” in Fig. in 1G:
PNG
media_image1.png
193
330
media_image1.png
Greyscale
The range in molecular weight between 158 kDa and 440 kDa, attributed to Peak 4 in instant paragraph [0027] does not possess specificity for identifying the trimeric form of p72.
In reply, applicant states the co-expression of p72 with its chaperone protein pB602L to achieve proper trimer folding is well-established in the art. Applicant asserts that Cui et al. (ACS Infect. Dis. 2025, of record) explicitly acknowledge that "the requirement for chaperone pB602L for folding" is required to achieve the trimeric form, as confirmed by the molecular sieve data in instant Figure 1 showing 71.79% trimer content. Applicant asserts that it is well-established knowledge in the art regarding p72-B602L co-expression, provides the skilled artisan with more than sufficient guidance to practice the invention without undue experimentation.
Applicant’s arguments and a review of the teachings of Cui et al. have been fully considered, but are found unpersuasive. In the paragraph bridging the pages prior to the “Results” heading, Cui et al. teach:
“previous attempts to utilize recombinant P72 in subunit vaccine development have been hindered by its tendency to form monomers rather than the more immunogenic native trimers and the requirement for chaperone pB602L for folding.”
noted by applicant. However, in the same paragraph, Cui et al. also state (emphasis underlined for convenience):
Notably, the membrane-bound and secreted P72 were able to fold into trimers independent of chaperone pB602L, and the membrane-bound and secreted penton also formed a native pentamer, therefore preserving their conformational epitopes. Immunogenicity testing in both mouse and pig models showed that the membrane-bound P72 and penton elicited significantly stronger antibody and T cell responses than their secreted or intracellular counterparts.
Expression of (intracellular) IC-P72; (secreted) S-72; and (membrane-bound) MB-P72 from Vero (eukaryotic) cells expression was confirmed by Western blot analysis at 1:2:8 by Cui et al., depicted in extended Figure 3B produced below:
PNG
media_image2.png
248
298
media_image2.png
Greyscale
Cui et al. clearly show that soluble (S-p72) and membrane-bound (MB-P72) are expressed at a statically significant higher fold than P72 expressed with chaperone, pB602L. The skilled artisan would not be able achieve a total content of trimeric p72 not less than 40% of the total content of the exterior envelope subunit protein p72 derived from ASFV, as required.
Applicant states the molecular weight of the p72 monomer is approximately 72 kDa and the theoretical molecular weight of approximately 216 kDa. Applicant points out that the size exclusion chromatography data in instant Figure 1 show Peak 4 at a retention volume of 15.84 mL and “71.79% of the total area, with a calculated molecular weight between 158 kDa and 440 kDa, which encompasses the expected molecular weight of a p72 trimer (~216-232 kDa). Applicant opines that the minor difference between 232 kDa of the instant invention and 240 kDa of Cui et al. is readily explained by different expression systems, i.e., insect cells sf9/ High Five cells of the instant invention compared with HEK293T cells of Cui et al.
Applicant’s arguments have been fully considered, but are found unpersuasive. It is not evident how an expected molecular weight between 216-232 kDa for p72 is determined from a calculated molecular weight ranging between 158 kDa and 440 kDa. It is not evident how a molecular weight of about 232 kDa for the instant p72 is surmised. The skilled artisan would not predict that the instant p72 is in trimeric from and is expressed at an expected molecular weight between 216-232 kDa from the data provided. Under “Recombinant Protein Production and Sample Preparation for P72 Trimer Characterization”, Cui et al. teach:
The recombinant P72 protein in the supernatant were collected and applied to the anti-HA Magnetic Beads (MCE, #HYK0201). The bound protein was washed with the resuspended buffer five times and then was eluted from the beads with a buffer containing 2 mg/mL HA peptide. The eluted sample was concentrated and further purified by Superdex 200 increase 10/300 GL size exclusion column (Cytiva 28990944) via capillary loop running in a buffer containing 20 mM HEPES at pH 7.4 and 300 mM NaCl. The P72 protein from size exclusion column peak was concentrated and kept at -80° C for future use.
Figure 1H of Cui et al.:
PNG
media_image3.png
266
246
media_image3.png
Greyscale
clearly shows the S-P72 and MP-P72 trimers eluting between 5-10 (mL) retention time instead of 15.84 retention time, as depicted in instant Figure 1:
PNG
media_image4.png
321
527
media_image4.png
Greyscale
Also see Extended Table 2 of Cui et al. reciting numerical retention (ml) and area (ml*mAU):
PNG
media_image5.png
287
911
media_image5.png
Greyscale
Trimer p72 profile elutions shown by Cui et al. inn Figure 1H and the p72 profile elution instantly depicted in Figure 1 do not explain the differences between p72 characterizations and cannot be attributed to mammalian (Cui et al.) versus insect cell (instant) expression, as applicant suggests.
Applicant argues that the instant 60% protection rate is achieved consistently across two independent vaccine formulations (Vaccines 3 and 4) with different trimer contents (40% and 71.79%), demonstrating the robustness and reproducibility of the claimed vaccine platform.
Applicant’s arguments and the data presented in the working examples have been fully considered, but are found unpersuasive because the instant specification does not sufficiently explain how the p72 and CD2v proteins are made or sufficiently describe what characteristics these subunit proteins have. The skilled artisan would have insufficient information to make and use the instant invention.
Applicant aligns the instant invention with the teachings of Cui et al. because
Cui et al. confirm that p72 trimer formation is achieved through co-expression with pB602L.
However, extended Figure 3B (below) of Cui et al. clearly show that soluble (S-p72) and membrane-bound (MB-P72) are expressed at a statically significant higher fold than P72 expressed with chaperone, pB602L.
PNG
media_image2.png
248
298
media_image2.png
Greyscale
Applicant points out that Cui et al. state that "immunogenicity was not assessed" and determination for whether trimeric p72 could provide protective efficacy was not assessed. Applicant posits that the present invention provides exactly this missing link.
Applicant’s arguments have been fully considered, but are found unpersuasive because the p72 and the p72 of Cui et al. are not the same.
Applicant criticizes Lopera-Madrid et al., of record because the HEK-purified p72 protein, may not have been properly folded into the native trimeric conformation, a critical distinction from the present invention where trimer content is specifically controlled and quantified.
Applicant’s arguments have been fully considered, but are found unpersuasive because the HEK-purified p72 induced ASFV-specific IgG-antibody responses in pigs, see 3.4. “ASFV antigen-specific antibody responses” and Figures 1 and 2. In the paragraph bridging the columns on page 30, Lopera-Madrid et al. teach “the administered antigens were authentic”.
Applicant argues that the instant invention overcomes the issues discussed by Gaudreault et al. (Vaccines 2019) and, separately, Lokhandwala et al., because the present invention combines CD2v with trimeric p72 in a specific adjuvant formulation, and the synergistic effect of this combination cannot be predicted from studies of CD2v alone. Moreover, Gaudreault et al. used Freund's adjuvant, and Lokhandwala et al. use ZTS-01, which are completely different adjuvants from the W/O/W emulsion adjuvant used in the present invention. The choice of adjuvant is well- known in vaccinology to critically affect both the magnitude and quality of the immune response.
Applicant’s arguments have been carefully considered, but fail to persuade because no synergism, i.e., more than additive, has been presented. In Table 1, Gaudreault et al. teach baculovirus-expressed subunit proteins, including p72, combined with Freund’s adjuvant (water-in-oil emulsion) resulted in a slight delay of clinical disease and viremia, but no protection. In section 3.2.1, Wu et al. review the teachings of Zajac et al., administering a mixture of ASFV antigens expressed from adenoviruses, combined with Montanide ISA-201™ (W/O/W emulsion), encompassed by the instant claims. Zajac et al. achieved a humoral immune response, but no protective efficacy after challenge. Wu et al. also review the administration of irradiation-inactivated ASFV (comprising p72 and CD2v) combined with Montanide ISA-201™, resulting increased antibody titers against p72, but no protection against challenge. While the adjuvants of and Lokhandwala et al. are different, one skilled in the art would not conclude therapeutic and protective efficacy, as asserted by the instant vaccine (described in instant paragraph [0022]).
Applicant contrasts the instant p72 with the p72 of Neilan et al. by stating that the instant p72 is in trimeric form.
Applicant’s arguments have been fully considered, however, the instant disclosure does not provide sufficient evidence that the instant p72 antigen is in trimeric form when comparing the elution peaks of Cui et al. and instant Figure 1.
Applicant argues that the adenovirus-vectored cocktail of 35 ASFV antigens of Cadenas-Fernández et al. and the 42 multiepitope ASFV antigens of Wu et al. are fundamentally different from the purified two-antigen subunit vaccine instantly claimed.
Applicant’s arguments have been carefully considered, however, the claims are not limited to two protein subunits because “the vaccine composition comprises” p72 and CD2v, and any other material in lines 2-3 of claim 1. Because the instant CD2v protein is glycosylated and expressed in a eukaryotic system, viral vectored-derived proteins combined in a cocktail formulation appear to be within the scope of the instant claims.
The state of the art indicates that African swine fever (ASF) is a viral disease of domestic and wild swine for which there is currently no vaccine or treatment available. For these reasons, it is determined that an undue quantity of experimentation would be required of the skilled artisan to make and use the invention claimed.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHANON A FOLEY whose telephone number is (571)272-0898. The examiner can normally be reached M-F, generally 5:30 AM-5 PM, flexible.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached at 571-270-3497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Shanon A. Foley/Primary Examiner, Art Unit 1671